Scotiabank Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS)

Stock analysts at Scotiabank started coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research note issued on Friday,Benzinga reports. The brokerage set a “sector outperform” rating and a $15.00 price target on the biotechnology company’s stock.

A number of other analysts have also commented on the company. Cantor Fitzgerald upgraded Aclaris Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Leerink Partners raised shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $2.00 to $7.00 in a report on Tuesday, November 19th. Leerink Partnrs upgraded Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 19th. StockNews.com lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 8th. Finally, Jefferies Financial Group upgraded shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and raised their price objective for the company from $2.00 to $7.00 in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Aclaris Therapeutics currently has an average rating of “Buy” and a consensus target price of $11.67.

Aclaris Therapeutics Stock Up 0.5 %

Shares of Aclaris Therapeutics stock opened at $1.83 on Friday. The company has a market cap of $197.49 million, a PE ratio of -3.52 and a beta of 0.48. The business has a 50 day moving average price of $2.34 and a 200-day moving average price of $2.18. Aclaris Therapeutics has a 52 week low of $0.95 and a 52 week high of $5.17.

Institutional Trading of Aclaris Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. ExodusPoint Capital Management LP purchased a new stake in Aclaris Therapeutics in the 4th quarter worth approximately $26,000. Invesco Ltd. bought a new stake in Aclaris Therapeutics during the 4th quarter valued at about $28,000. Graham Capital Management L.P. purchased a new stake in shares of Aclaris Therapeutics during the fourth quarter valued at $35,000. Commonwealth Equity Services LLC purchased a new position in shares of Aclaris Therapeutics during the fourth quarter valued at approximately $36,000. Finally, Alpine Global Management LLC purchased a new stake in Aclaris Therapeutics during the 4th quarter valued at $38,000. Institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.